MacroGenics, Inc. (NasdaqGS: MGNX)
Health Care · Biotechnology · US
$3.74
+5.35% today · +113.7% 1Y
MacroGenics, Inc. (NasdaqGS: MGNX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $238.24M and employs 293 people.
Over the last twelve months the share price has gained 113.7%, trading between 1.29 and 5.08.
Tweenvest scores MacroGenics, Inc. across four factors: quality 42/100, value 67/100, growth 0/100. Its strongest factor is value.
MGNX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $238.24M
- Revenue (TTM)
- $175.14M
- P/E
- —
- EPS
- -0.23
- Dividend yield
- —
- Beta (5Y)
- 1.21
- 52-week high
- $5.08
- 52-week low
- $1.29
- Avg volume (3M)
- —
- Shares outstanding
- 63.70M
- Employees
- 293
- Next earnings
- —
About MacroGenics, Inc.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
- ISIN
- US5560991094
- Founded
- 2000
- Listed since
- Oct 10, 2013
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Polaris GroupTWSE: 6550 | $242.78M | NT$16.70 | -0.30% |
| Greenwich LifeSciences, Inc.NasdaqCM: GLSI | $242.63M | $16.53 | -2.65% |
| Pyxis Oncology, Inc.NasdaqGS: PYXS | $242.50M | $2.03 | -5.14% |
| SillaJen, Inc.KOSDAQ: A215600 | $241.16M | ₩2,340.00 | -0.85% |
| Keros Therapeutics, Inc.NasdaqGM: KROS | $236.93M | $11.95 | +5.19% |
| Sutro Biopharma, Inc.NasdaqGM: STRO | $236.61M | $14.27 | -7.04% |
| Camp4 Therapeutics CorporationNasdaqGM: CAMP | $236.58M | $3.77 | -5.75% |
| InflaRx N.V.NasdaqGS: IFRX | $235.79M | $1.60 | +4.58% |
Figures last refreshed Oct 11, 2026.